Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial
Berend J. van der Wilk(Erasmus MC Cancer Institute), J.J.B. van Lanschot(Erasmus MC), Liekele E. Oostenbrug(Zuyderland Medisch Centrum), Erik J. Schoon(Radboud University Nijmegen), Manon C.W. Spaander(Erasmus University Rotterdam), Kausilia K. Krishnadath, Katharina Biermann(Rotterdam University of Applied Sciences), Sjoerd M. Lagarde(University of Amsterdam), Ben M. Eyck(Erasmus MC Cancer Institute), B.P.L. Wijnhoven(Erasmus MC), Michail Doukas(Erasmus MC), Leendert H. J. Looijenga(University Medical Center Utrecht)
Cited by 20
Related Papers
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Intragenic ERBB2 kinase mutations in tumours
|Nature|2004|790
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|788